Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Leukemia, Myeloid, Chronic-Phase 7Breast Neoplasms 6Leukemia 5Blast Crisis 4Philadelphia Chromosome 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Leukemia, Myeloid, Accelerated Phase 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Translocation, Genetic 1Thymus Neoplasms 1Thymoma 1Pathologic Processes 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

Imatinib Mesylate 14Dasatinib 5nilotinib 4Cyclophosphamide 4fludarabine 3bosutinib 3Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2fludarabine phosphate 2asciminib 2Prednisone 2Daunorubicin 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1ponatinib 1olverembatinib 1flumatinib 1blinatumomab 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Philadelphia Chromosome × bosutinib × Clear all
NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00261846 2017-07-27

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Pfizer

Phase 2 Completed
571 enrolled 48 charts
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡